Allogeneic Stem Cell Therapy for Acute Ischemic Stroke
Authors: Kiyohiro Houkin, Toshiya Osanai, Shinichiro Uchiyama, Kazuo Minematsu, Akihiko Taguchi, Katsuhiko Maruichi, Yoshimasa Niiya, Katsuyuki Asaoka, Yoshihiro Kuga, Katsumi Takizawa, Koichi Haraguchi, Shinichi Yoshimura, Kazumi Kimura, Koji Tokunaga, Atsuo Aoyama, Fusao Ikawa, Chikanori Inenaga, Tatsuya Abe, Atsushi Tominaga, Shinichi Takahashi, Kohsuke Kudo, Miki Fujimura, Taku Sugiyama, Masaki Ito, Masahito Kawabori, David C. Hess, Sean I. Savitz, Teruyuki Hirano, Kiyohiro Houkin, Toshiya Osanai, Katsuhiko Maruichi, Yoshimasa Niiya, Katsuyuki Asaoka, Katsumi Takizawa, Kouichi Haraguchi, Rokuya Tanikawa, Akira Tempaku, Yusuke Shimoda, Masanori Isobe, Kenji Kamiyama, Masafumi Ohtaki, Norihito Shimamura, Junta Moroi, Aiki Marushima, Shinichi Takahashi, Takao Urabe, Teruyuki Hirano, Kazumi Kimura, Kazuo Kitagawa, Hidetoshi Kasuya, Yoshikane Izawa, Yasuyuki Iguchi, Koichi Oki, Koichi Kato, Yoshihisa Yamano, Satoshi Kuroda, Atsushi Sato, Chikanori Inenaga, Keizo Yasui, Kazunori Toyoda, Shinichi Yoshimura, Nobuyuki Sakai, Yoshihiro Kuga, Atsuo Aoyama, Fusao Ikawa, Koji Tokunaga, Atsushi Tominaga, Yasushi Takagi, Masahiro Yasaka, Tatsuya Abe, Takayuki Matsuo, Toshiro Yonehara, Tadashi Terasaki, Hideki Matsuoka
Journal: JAMA Neurology (2024)

Importance Cell therapy is a promising treatment approach for stroke and other diseases. However, it is unknown whether MultiStem (HLCM051), a bone marrow–derived, allogeneic, multipotent adult progenitor cell product, has the potential to treat ischemic stroke. Objective To assess the efficacy and safety of MultiStem when administered within 18 to 36 hours of ischemic stroke onset. Design, Setting, and Participants The Treatment Evaluation of Acute Stroke Using Regenerative Cells (TREASURE) multicenter, double-blind, parallel-group, placebo-controlled phase 2/3 randomized clinical trial was conducted at 44 academic and clinical centers in Japan between November 15, 2017, and March 29, 2022. Inclusion criteria were age 20 years or older, presence of acute ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] score of 8-20 at baseline), confirmed acute infarction involving the cerebral cortex and measuring more than 2 cm on the major axis (determined with diffusion-weighted magnetic resonance imaging), and a modified Rankin Scale (mRS) score of 0 or 1 before stroke onset. Data analysis was performed between May 9 and August 15, 2022. Exposure Patients were randomly assigned to either intravenous MultiStem in 1 single unit of 1.2 billion cells or intravenous placebo within 18 to 36 hours of ischemic stroke onset. Main Outcomes and Measures The primary end points were safety and excellent outcome at day 90, measured as a composite of a modified Rankin Scale (mRS) score of 1 or less, a NIHSS score of 1 or less, and a Barthel index score of 95 or greater. The secondary end points were excellent outcome at day 365, mRS score distribution at days 90 and 365, and mRS score of 0 to 1 and 0 to 2 at day 90. Statistical analysis of efficacy was performed using the Cochran-Mantel-Haenszel test. Results This study included 206 patients (104 received MultiStem and 102 received placebo). Their mean age was 76.5 (range, 35-95) years, and more than half of patients were men (112 [54.4%]). There were no between-group differences in primary and secondary end points. The proportion of excellent outcomes at day 90 did not differ significantly between the MultiStem and placebo groups (12 [11.5%] vs 10 [9.8%], P = .90; adjusted risk difference, 0.5% [95% CI, −7.3% to 8.3%]). The frequency of adverse events was similar between treatment groups. Conclusions and Relevance In this randomized clinical trial, intravenous administration of allogeneic cell therapy within 18 to 36 hours of ischemic stroke onset was safe but did not improve short-term outcomes. Further research is needed to determine whether MultiStem therapy for ischemic stroke has a beneficial effect in patients who meet specific criteria, as indicated by the exploratory analyses in this study. Trial Registration ClinicalTrials.gov Identifier: NCT02961504